ArticleMolecular medicine (Cambridge, Mass.)2026
Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundMyelofibrosis (MF) is a rare and severe myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenia, extramedullary hematopoiesis, and systemic inflammation. The tumor microenvironment (TME) plays a crucial role in MF pathogenesis by promoting fibrotic remodeling and supporting malignant clone survival. Among the key mediators of intercellular communication within the TME are extracellular vesicles (EVs), which transport bioactive molecules such as proteins, lipids, and nucleic acids. EVs derived from both malignant and stromal cells might contribute to disease progression and niche remodeling in MF. However, their role in MF TME has still to be defined.
methodsEVs were isolated from the platelet-poor plasma of MF patients and age- and sex-matched controls using size-exclusion chromatography. EVs were then characterized by transmission electron microscopy, nanoparticle tracking analysis, and Western blotting for canonical markers, following with the surface protein profiling using bead-based flow cytometry, and lipidomic profiling by liquid chromatography-mass spectrometry. Functional assays assessed the impact of EVs on α-smooth muscle actin (α-SMA) expression in Transforming Growth Factor (TGF)-β–stimulated fibroblasts.
resultsEVs from MF patients displayed typical EV features (CD9, TSG101, and ALIX positivity) and showed a significant increase in median size compared with control counterparts, suggesting altered vesicle biogenesis. Lipidomic analysis identified 136 species across 12 lipid classes, revealing a distinct MF-specific lipid signature characterized by reduced sphingomyelin levels and increased diacylglycerol, ether-linked phosphatidylcholine, and phosphatidylethanolamine species, as well as enhanced acyl chain unsaturation, indicative of membrane remodeling under inflammatory stress. Surface profiling analysis revealed that MF-derived EVs exhibited a selective depletion of the endothelial marker CD146. Functionally, control-derived EVs significantly suppressed α-SMA expression in TGF-β–stimulated fibroblasts, whereas MF-derived EVs failed to exert this effect, suggesting a loss of regulatory function.
conclusionThe integrated biophysical, molecular, and functional characterization of circulating EVs in MF revealed a distinct signature marked by enlarged vesicle size, altered lipid and protein composition, and reduced ability to counteract a fibrosis-related phenotype. These findings support a potential role for circulating EVs in promoting marrow fibrosis and highlight their promise as a liquid biopsy approach for identifying biomarkers and potential therapeutic targets in MF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.